---
title: "Weekly Recap | AstraZeneca -5.81%, $2bn oncology bet"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300846472.md"
description: "AstraZeneca (AZN) fell 5.81% this week to close at $156.90, down from the prior close of $166.58 on Friday, September 25. The five sessions drifted lower almost in a straight line. Monday opened at $165.69 and briefly touched a weekly high of $167.52, but the stock eased every day after that, bottoming at $156.41 on Friday before settling at $156.90. Weekly amplitude came to 6.71% on about 13.7m shares, a touch below the 60-day daily average."
datetime: "2026-10-03T06:21:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300846472.md)
  - [en](https://longbridge.com/en/news/300846472.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300846472.md)
generator: "portal-rs"
---

# Weekly Recap | AstraZeneca -5.81%, $2bn oncology bet

## The Week

AstraZeneca (AZN) fell 5.81% this week to close at $156.90, down from the prior close of $166.58 on Friday, September 25. The five sessions drifted lower almost in a straight line. Monday opened at $165.69 and briefly touched a weekly high of $167.52, but the stock eased every day after that, bottoming at $156.41 on Friday before settling at $156.90. Weekly amplitude came to 6.71% on about 13.7m shares, a touch below the 60-day daily average.

## Key Events

The week’s biggest story was oncology. AstraZeneca announced a $2bn equity investment in Summit Therapeutics and signed a clinical collaboration to test the ADC sonesitatug vedotin with ivonescimab in gastrointestinal cancers. Daiichi Sankyo then joined the two companies in a broader trial pact evaluating Datroway in combination with Ivonescimab across multiple tumour types. The news sent Summit shares up more than 17% over the week, while AstraZeneca itself lost ground as investors signalled mixed views on the immediate return from the $2bn outlay. Elsewhere, after AstraZeneca mounted a legal challenge, a rival drug to Tagrisso lost EU approval, removing a potential competitive threat to the company’s core lung-cancer asset.

## Analyst Ratings

Eleven firms cover AstraZeneca. Seven rate it buy, three rate it outperform, and one rates it hold; none rate it underperform or sell. The consensus rating is strong buy, with a consensus target of $212.17, roughly 35.23% above the $156.90 spot. Targets range from $184 to $240, so the spread remains wide. Within the pharmaceutical sector, AstraZeneca ranks 35th out of 203 companies, placing it in the upper part of the group.

## The Week Ahead

On the macro side, several US data points land next week: the S&P Global services PMI final and ISM non-manufacturing PMI on Monday, October 5, the trade deficit on Tuesday, October 6, and weekly EIA crude inventories on Wednesday, October 7. On the company side, AstraZeneca reports fiscal Q3 2026 earnings before the open on October 30, with consensus estimates around $1.17 per share and $16.1bn in revenue. That print will be the next test of whether the oncology spending and core growth can move together.

## In Short

The week’s signals are split. The analyst side stays firmly in strong buy territory, with the consensus target more than a third above spot, suggesting confidence in the oncology pipeline. Yet the stock fell through the week, as the market gave a muted reception to the $2bn equity investment and its near-term payoff. What to watch next is whether AZN can stabilise the share-price rhythm after removing a Tagrisso rival from the EU market, and how the late-October earnings read guides the next leg.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)

## Related News & Research

- [AstraZeneca Tracks Real-World Sinus Surgery Outcomes in China: What Investors Should Watch](https://longbridge.com/en/news/286132902.md)
- [AstraZeneca: Tagrisso Plus Orpathys Phase III Trial Shows PFS, OS Improvements In EGFRm Lung Cancer](https://longbridge.com/en/news/296071807.md)
- [Peter Schiff Warns Trump’s ‘Booming’ Stock Market Boast Is a Mirage: 479 Stocks Hit 52-Week Lows on Wednesday, While Only 60 Set Highs](https://longbridge.com/en/news/301958076.md)
- [Why Is Rocket Lab Stock Plunging in Premarket Today? What This Top Analyst Sees Next](https://longbridge.com/en/news/301962657.md)
- [CRWV vs. NBIS: Which Neocloud Stock Offers More Upside as the AI Sell-Off Continues?](https://longbridge.com/en/news/301970902.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**